After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering ...

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in ...

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.